COO

Over the past six months, The Cooper Companies' stock experienced significant fluctuations, gaining 22.2% from April to August 2026 due to resilient contact lens demand and a recovery in fertility markets, outperforming industry benchmarks. During Q2 2026, revenues increased 8% to a record $1.08 billion, and adjusted EPS rose 26% to $1.21, marking its tenth consecutive quarter of beating expectations. However, the stock declined 21.14% from August 19 to October 5, 2026, and saw its weakest single-period move on September 10, 2026, dropping 14.67%. As of September 18, 2026, the share price was $55.29, an 18.89% decline over the previous year. Key events impacting the stock included the Q3 2026 earnings release on September 9, 2026, where EPS topped estimates but revenue missed, causing a 17% after-hours drop. In September 2026, the company finalized its strategic review, deciding to retain the CooperSurgical unit and expanding its share repurchase program from $2 billion to $3 billion. Several analysts lowered price targets and ratings in September and October 2026, with Zacks Research cutting the rating to a 'strong sell' while Barclays and Weiss Ratings upgraded to a 'hold.' Concerns about U.S. channel inventory reductions and a 6% decline in CooperVision revenues in the Asia-Pacific region due to softer demand in Japan and China were also cited as factors driving the stock lower.